A real-time and modular approach for quick detection and mechanism exploration of DPIs with different carrier particle sizes.

Dry powder inhalers (DPIs) had been widely used in lung diseases on account of direct pulmonary delivery, good drug stability and satisfactory patient compliance. However, an indistinct understanding of pulmonary delivery processes (PDPs) hindered the development of DPIs. Most current evaluation methods explored the PDPs with over-simplified models, leading to uncompleted investigations of the whole or partial PDPs. In the present research, an innovative modular process analysis platform (MPAP) was applied to investigate the detailed mechanisms of each PDP of DPIs with different carrier particle sizes (CPS). The MPAP was composed of a laser particle size analyzer, an inhaler device, an artificial throat and a pre-separator, to investigate the fluidization and dispersion, transportation, detachment and deposition process of DPIs. The release profiles of drug, drug aggregation and carrier were monitored in real-time. The influence of CPS on PDPs and corresponding mechanisms were explored. The powder properties of the carriers were investigated by the optical profiler and Freeman Technology four powder rheometer. The next generation impactor was employed to explore the aerosolization performance of DPIs. The novel MPAP was successfully applied in exploring the comprehensive mechanism of PDPs, which had enormous potential to be used to investigate and develop DPIs.

Introduction

Dry powder inhalers (DPIs) had raised extensive attention in the world, allowing directly administration to deep lung for high local drug concentrations, and systematic drug absorption without first-pass effect. However, insurmountable technical barriers due to lacking of fundamental process-related theories, high cost and long production cycle had restricted the development of DPIs. A few studies roughly summarized the pulmonary delivery processes (PDPs) of DPIs, which could be divided into four processes (Fig. 1): fluidization and dispersion of DPIs in the inhaler device, transportation of DPIs through oropharynx and throat, detachment of APIs from the carriers, in bronchi and deposition of APIs in the lung. However, the detailed mechanism of PDPs was unclear owing to the lack of efficient evaluation approaches, so the gap between the theories and the DPIs development still existed.

Figure 1

Schematic diagram of the pulmonary delivery processes of carrier-based DPIs.

In general, the most common evaluation approaches of PDPs were Next Generation Impactor (NGI, Copley Scientific Ltd., Nottingham, UK) and computational fluid dynamic-discrete element method (CFD-DEM). NGI was widely recognized by the pharmacopoeia of several countries6, 7, 8. The common indicators such as aerodynamic diameter (dae), fine particle fraction (FPF), fine particle dose (FPD), emitted dose (ED), mass median aerodynamic diameter (MMAD) values and drug deposition profiles could be obtained by NGI, which served as indicators of aerosolization performance of DPIs. Nevertheless, only the final deposition state of DPIs could be detected by NGI instead of real-time monitoring, so it was hard to provide more detailed information for the PDPs of DPIs. Moreover, it was time and labor consuming to conduct NGI tests since the complicated operation and followed up quantification required an entire day for only one measurement, and thus severely hampered the efficiency of the industrialization processes. CFD-DEM model was a powerful tool to simulate the behavior of fluid–particle interactions, and was successfully employed in DPIs to aid the analyzing particle motion in the inhaler devices, throat and bronchi 3D models,. However, the crucial physical properties, such as the particle shape, surface roughness and particle size distribution, were often over simplified in CFD-DEM model. In addition, the model development was a drawn-out process. Moreover, most of the CFD-DEM models only focused on partial PDPs without covering the whole processes consecutively and therefore, failed to provide detailed and integrated mechanisms of PDPs. In view of the insufficient information, low efficiency and the high cost of the present evaluation approaches, it was of great academic and industrial importance to develop a novel approach to investigate the PDPs of DPIs.

The modular process analysis platform (MPAP), developed in our previous research, demonstrated a potential to reach this goal. Previously, MPAP was applied to explore the influence of air flow rate during the PDPs. The detailed mechanisms of air flow rate for PDPs of DPIs were successfully demonstrated, whose reliability was also preliminarily verified by NGI. This approach was competent to provide adequate and detailed information, with low cost and high efficiency. Specifically, it realized real-time monitoring of PDPs of DPIs in the inhaler device, throat and bronchi separately, which was the indispensable prerequisite for efficient optimization of DPIs. Except for the air flow rate, there were some other key factors that influenced the PDPs such as the physicochemical properties of carriers16, 17, 18 and parameters of inhaler devices. It was noteworthy that carriers served as the fundamental component of carrier-based DPIs due to their high proportions in the formulations. Slight changes in the physical properties of carriers had enormous impacts on the PDPs. Among those properties, carrier particle size (CPS) was one of the most important factors, and was relatively easy to adjust in actual DPIs manufacturing to satisfy various formulation compositions.

CPS exercised great influence on PDPs of DPIs. The gravitational force (FG) and inertia of carrier varied with different CPS, which would lead to premature deposition of DPIs in the inhaler device or throat to different extents. Besides, the numbers of active sites on the particle surface and surface roughness of carriers associated with the CPS, which directly altered the inter-particulate force (FI) between carrier–carrier and carrier‒APIs. Thus, they affected the dispersibility of the particles, the following carrier detachment and drug delivery efficiency. Some researchers suggested that the FPF increased with smaller carrier particle size due to weaker adhesive force,. In contrast, others reported that improvement in aerosolization performance was observed with larger-sized carrier because of the superior dispersibility and longer residence time. Meanwhile, some studies demonstrated that the impact of CPS varied with the different shapes of carriers or the different inhaler devices. Despite of the importance of CPS, the detailed PDPs mechanism of DPIs with different CPS had not yet reported. As a matter of fact, the available studies proposed contradictory and inconclusive results. They might be caused by the different sieving methods of carrier, drug proportion or inhaler devices, which needed to be unified to investigate the effect of CPS.

In the present study, MPAP was applied to explore the effect of CPS and the mechanisms in the PDPs of DPIs. The reliability of MPAP was further demonstrated and its potential in optimizations of DPIs was studied. As shown in Fig. 2, MPAP was composed of a laser particle size analyzer (Fig. 2A, Sympatec HELOS, Sympatec GmbH, Clausthal-Zellerfeld, Germany), an inhaler device, an artificial throat and a pre-separator (Fig. 2B). The inhaler device was employed to assess the fluidization and dispersion processes of DPIs. The transportation of DPIs in the bended structure of human throat was mimicked by the artificial throat, which changed the orientation of air flow. Moreover, the bronchi bifurcation was simulated by the pre-separator, where the detachment mainly happened. Using real formulations in the MPAP test guaranteed the obtained results of physical properties of carriers or drugs were not simplified. Meanwhile, the release profiles of drug, drug aggregation and carrier could be monitored in real-time by the time-sliced measurement of MPAP, so that the function of each component in PDPs could be investigated. Notably, high efficiency and low cost of PDPs measurement were achieved by MPAP with quick detection (about 1 min) and small amount of sample (as low as 10 mg), which was beneficial for preliminary optimizations and quality control of DPIs manufacturing. In addition, Freeman Technology 4 (FT4) Powder Rheometer (Freeman Technology, Tewkesbury, UK) and NGI were employed to explore the powder flow properties of carriers and the aerosolization performance of DPIs respectively, which served as a reference to interpret and verify the results of MPAP. A good linear relationship was established between the results of NGI and MPAP, which confirmed the reliability and feasibility of MPAP for DPIs design and optimization.

Figure 2

Schematic diagrams of MPAP (A) Laser particle size analyzer; (B) Changeable module.

Materials and methods

Materials

Lactose (LAC) including Inhalac® 251, Inhalac® 230 and Inhalac® 120 were generously donated by Meggle Pharma Co., Ltd. (Wasserburg, Germany). Salbutamol sulfate was obtained from Bidepharmatech Co., Ltd. (Shanghai, China). Hydroxy propyl methyl cellulose (HPMC) capsules 3# Vcaps® were generously donated by CAPSUGEL Co., Ltd. (Suzhou, China). Acetonitrile (analytically pure grade) was obtained from Saen Chemical Technology Co., Ltd. (Shanghai, China). Methanol (analytically pure grade) was obtained from Honeywell Burdick & Jackson, Inc. (Morris, NJ, USA). Monopotassium phosphate was supplied by Damao Chemical Reagent Factory Co., Ltd. (Tianjin, China).

Preparation of model DPIs

Micronization of salbutamol sulfate

Salbutamol sulfate was jet-milled by J-20 (TECNOLOGIA MECCANICA, Italy) with 6 kPa ring pressure and 7 kPa venturi pressure. Micronized salbutamol sulfate (MSS) was obtained and chosen as the model drug in the present study.

Sieving of lactose carrier

The commonly used inhalation lactose Inhalac 251, 230 and 120 were chosen to produce carriers of DPIs. They were produced from the same batch of lactose by sieving, which avoided the effect of different technological parameters. In the present study, they were sieved to obtain LAC with different particle size fractions (PSF). The targeted PSF, raw material and mesh size of sieve was presented in Table 1. They were placed on a mesh (200 μm) on mechanical shaker (AS200, RETSCH, Haan, Germany) and shaken for 2 min. Powder remained on the top of each different sieve (150, 100, 75 and 45 μm) was further subjected to air jet sieving (HOSOKAWA Micron Powder Systems, New Jersey, USA)) for 2 min to remove fine powder. When the sieving process was completed, LAC with different PSF was obtained.

Table 1

Sieving of lactose carrier.

Formulation	Targeted PSF (μm)	Raw material	Mesh size for air jet sieving (μm)	Mesh size for mechanical shaker (μm)
–	–	–	–	45
LAC1	45–75	Inhalac 251	45	75
LAC2	75–100	Inhalac 230	75	100
LAC3	100–150	Inhalac 120	100	150
LAC4	150–200	Inhalac 120	150	200

‒Not applicable; PSF, particle size fraction; LAC, lactose.

Particle size distribution

The particle size distribution of MSS and LAC1‒4 was measured by Sympatec HELOS&INHALER (Sympatec Gmbh, Clausthal-Zellerfeld, Germany). A single dose inhaler device Turbospin® (PH&T S.p.A., Milan, Italy) was used for dispersion and inserted into the adapter of INHALER. Start of the measurements was triggered by an optical concentration (C.OPT) larger than 0.3% and stopped at C.OPT smaller than 0.1%. The measurements were performed under air flow rate (U0) of 60 L/min. R2 lens with a measurable particle size range of 0.25/0.45–87.5 μm and R4 lens with a measurable particle size range of 0.5/1.8–350 μm were chosen to detect the particle size distribution of MSS and LAC1‒4, respectively. Meanwhile, the WINDOX software was used to control the measurement and analyze the results with the high-resolution Fraunhofer model. Three repeat measurements were conducted for each sample.

Preparation of model DPIs

The model DPIs were fabricated by blending MSS and LAC1‒4 at a ratio of 1:15 (w/w) respectively, which were termed as DPI1, DPI2, DPI3 and DPI4. A Turbula T2F mixer (Glen Creston Ltd., Middlesex, UK) was applied for blending at 46 rpm for 60 min. The obtained model DPIs were packed into 3#Vcaps® capsules with 10 ± 0.5 mg. The homogeneity of each model DPIs was evaluated (Supporting Information Section 1).

Surface roughness and morphology

A ContourGT Optical Profiler (Bruker Optics Inc., Billerica, USA) was used to measure the degree of surface roughness of LAC. Magnification lens (5 × , interferometry) with back scan equaled to 20 μm and the length of scanning equaled to 20 μs. The scanning area was 46.90 μm × 62.53 μm for all LAC samples. The average roughness (Ra), maximum profile valley depth (Rv) and maximum profile peak height (Rp) were obtained.

The morphology and chemical element distribution of MSS, LAC and model DPIs were examined by Gemini 500 scanning electron microscope (SEM, Bruker Optics Inc., Billerica, USA) equipped with energy-dispersive X-ray spectroscopy (EDXS). Samples were placed on aluminum stubs prior to imaging. The SEM and EDXS images were captured at an acceleration voltage of 3.0 and 6.0 kV, respectively. Oxygen (O) spectra and sulfur (S) spectra images were captured by EDXS, which represented LAC (C12H22O11) and MSS [(C13H21NO3)2·H2SO4], respectively.

Powder flow properties measurement

The powder flow properties of LAC were characterized by FT4 Powder Rheometer (Freeman Technology). The standard dynamic test, aeration test and permeability test were conducted, and a conditioning cycle that removed the packing history and operator differences was performed before all the tests. The detailed method of FT4 was presented in Supporting Information Section 2. All the measurements were performed in triplicate.

The effect of CPS on pulmonary delivery processes of DPIs: MPAP

Three different configurations of MPAP were set up to explore the PDPs of DPIs with various CPS in inhaler device (Fig. 3A), artificial throat (Fig. 3B) and pre-separator (Fig. 3C). The single dose Turbospin® was selected as model inhaler device. The inhaler resistance of Turbospin® was 59.8 L/min when P1 of NGI was set to 4.0 kPa as the pressure of human lung. The measurements were conducted under the U0 of 60 L/min with the following parameters. Start and stop of the measurements was triggered on a C.OPT of 1.0% and 1.0%, respectively. A R4 lens was applied to the measurements and the duration was 4 s. The data were recorded in 100 ms sections with a 50 ms time base. Each sample was quantified in triplicate. WINDOX 5.0 software was used for data analysis. The involved parameters were descripted in Supporting Information Section 3. The product of C.OPT and dQ3 was defined as release amount (R) of particles, which was recorded in each 100 ms. Release profile was plotted by time (T) as X-axis and R as Y-axis, and points were connected by smooth curves. The area under the curve of release profile was integrated by Origin 8.5 Software (Origin Lab, Northampton, MA, USA), which was defined as RAUC.

Figure 3

Schematic illustration of (A) Configuration A: laser particle size analyzer with inhaler device; (B) Configuration B: laser particle size analyzer with inhaler device & artificial throat; (C) Configuration C: laser particle size analyzer with inhaler device & artificial throat & pre-separator.

In vitro aerosolization performance: NGI

The in vitro aerosolization performance of model DPIs was evaluated by NGI. Turbospin® and Tween® 80 (1% in ethanol, v/v) were selected as the inhaler device and surface coating of NGI stages. A batch of 20 capsules of each model DPIs were shot in each run under air flow rate of 60 L/min for 4 s. Ultra-pure water was used to collect MSS and LAC deposition on the inhaler device, adaptor, induction port, pre-separator, all NGI stages and micro orifice collector (MOC). The deposition profile of MSS and LAC was obtained by high performance liquid chromatography (HPLC) quantification. The experiments were conducted in triplicates. The FPF values were calculated by CITDAS® software (version 3.10, Copley Scientific Ltd., Nottingham, UK).

Statistics analysis

All the data were showed as mean ± standard deviation (SD), if possible. SPSS Statistics V 17.0 software (IBM Corporation, Armonk, NY) was employed for statistical analysis. One-way analysis of variance (ANOVA) and unpaired two-sample t-test were used to data analysis. P value higher than 0.05 was determined as statistically significance. Besides, R value higher than 0.9 suggested a strong correlation.

Results and discussion

Particle size distribution

Particle size distributions of LAC and MSS are shown in Table 2. The D50 values of MSS are smaller than 5 μm, indicating the suitability of the MSS in pulmonary drug delivery. Moreover, particle size distributions of LAC were far larger than MSS and not overlapping. It suggested that LAC and MSS could be distinguished by MPAP and were able to be used in the following studies.

Table 2

Particle size distribution of LAC and MSS.

Formulation	D10 (μm)	D50 (μm)	D90 (μm)	Span
MSS	1.15 ± 0.04	2.88 ± 0.10	7.72 ± 0.60	3.08 ± 0.12
LAC1	41.66 ± 0.14	65.97 ± 0.12	91.70 ± 1.55	2.02 ± 0.02
LAC2	67.33 ± 1.15	99.87 ± 0.27	132.92 ± 0.41	2.01 ± 0.01
LAC3	86.31 ± 0.66	124.33 ± 0.35	160.11 ± 0.30	1.98 ± 0.01
LAC4	98.96 ± 2.23	152.30 ± 0.50	194.17 ± 0.47	1.92 ± 0.02

All data were presented as mean ± SD, n = 3. LAC, lactose; MSS, micronized salbutamol sulfate.

The D10‒D90 of MSS and LAC obtained from Sympatec HELOS&INHALER served as a reference of the primary size of drug and carrier. Particles with the size range from D90 of MSS to D10 of LAC were defined as drug aggregation. The results are present in Table 3.

Table 3

The primary particle size of drug, drug aggregation and carrier.

Formulation	Primary particle size (μm)
MSS	1.15–7.72
LAC1	41.66–91.70
Drug aggregation-1	7.72–41.66
LAC2	67.33–132.92
Drug aggregation-2	7.72–67.33
LAC3	86.31–160.11
Drug aggregation-3	7.72–86.31
LAC4	98.96–194.17
Drug aggregation-4	7.72–98.96

LAC, lactose; MSS, micronized salbutamol sulfate.

The 3D images of LAC surfaces acquired by optical profiler are presented in Fig. 4A and the corresponding Ra values are shown in Fig. 4B. The surface of LAC1 was covered by serried and uniform projections with a few deep voids, which possessed the lowest Ra among all LAC samples. With the increase of particle size, some scattered large peaks appeared on the LAC2 surface, while majority of the surface was still covered with dense and small projections. The number of large peaks kept increasing in LAC3 and their distribution tended to be even. Meanwhile, there were many deep voids (blue color) appeared in LAC3, suggesting the increased roughness of surface and thus increased Ra. Furthermore, the highest density of large peaks showed up on the surface of LAC4, which resulted in the highest value of Ra. In summary, the density of large peaks on the surface increased with the increased particle size of LAC, and the Ra values presented the same tendency. The SEM images of LAC (Supporting Information Section 4) demonstrate the same results that the surface roughness (e.g., granular structures and local projections) increased with larger LAC particle size.

Figure 4

(A) 3D images of LAC surfaces; (B) Ra of LAC surfaces; (C) Schematic diagram of LAC with different Ra; (D) SEM images of (a) MSS and (c) LAC. EDXS images of (b) MSS and (d) LAC; (E) EDXS images of DPI1‒DPI4 (All data were presented as mean ± SD, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.005, n = 3).

The EDXS images of LAC, MSS and DPI1‒DPI4 are presented in Fig. 4D and E. Fig. 4Da and 4Dc are the optical images of MSS and LAC, respectively, which served as the comparisons of their S and O spectra images. The yellow and purple colors represent S atoms of MSS (Fig. 4Db) and O atoms of LAC (Fig. 4Dd), respectively. The merged images of DPIs (Fig. 4E) show that drug particles (yellow color) were evenly distributed on the carrier surface (purple color) of DPI1 and DPI2, while some drug particles scattered. Besides, when the CPS of DPIs increased as well as Ra, drug particles tended to mainly distribute in the deep voids of carrier. Moreover, the results of EDXS are also exemplified by the SEM images of DPIs (Supporting Information Section 4).

Some studies27, 28, 29, 30 have confirmed that the Ra of carrier was relevant to the adhesive force between carrier and drug in carrier-based DPIs, which affected the detachment process in the pulmonary delivery. The Ra value had a great impact on the interaction between carrier and drug. The larger Ra led to higher adhesive force due to larger contact area, which was defined as the active sites,. Due to the serried and uniform projections on LAC1 and most part of LAC2 surface, the degree of surface discontinuities was too small to allow the drug particles to insert into the tiny cavities on the surface and consequently, the contact area between drug and carrier and the corresponding adhesive force were small (Fig. 4C). On the contrary, the projections on the carrier surface became larger and taller when particle size increased, forming big cavities on the surface. In this case, drug particles could easily imbed into the cavities and adhere to the carrier by mechanical interlocking. Meanwhile, the contact area between drug and carrier became larger, resulting in the increase of the Van der Waals force and the Coulomb force, which might intensify the interaction between drug and carrier but also, hinder the detachment of drug and carrier (Fig. 4C). For LAC1‒4, the results indicate that the carrier with smaller particle size had lower Ra, which would be beneficial to the detachment process in pulmonary delivery of DPIs.

Powder flow properties

The FT4 powder rheometer was used to investigate the powder flow properties of LAC. The TE, BFE and SE values obtained from dynamic tests are shown in Fig. 5A. The TE values were increased with the growth of LAC particle size, which served as an indicator of flow resistance (Fig. 5Aa). It revealed that LAC with smaller particle size showed lower resistance to air flow, representing superior flowability. When the particle size of LAC was larger, the mass of particles increased and the FG acted on each particle was increased. Thus, the press-on force (FP) acted on the under particles was greater as well. In addition, the Ra values climbed up with the increment of particle sizes, which indicating larger friction coefficients. Hence, the friction force (FF) increased between particles of LAC with larger particle sizes as shown in Eq. (1):where μ represents the friction coefficient of the contact surface.

Figure 5

(A) Dynamic test results of LAC. (a) Total energy (TE) vs. dynamic profiles; (b) Basic flow energy (BFE); (c) Specific energy (SE); (d) Schematic diagram of blade and LAC during dynamic test; (e) Force analysis of LAC during dynamic test; (B) Aeration test results of LAC. (a) TE vs. aeration profiles of LAC1‒3; (b) TE vs. aeration profiles of LAC4; (c) Aerated energy (AE); (d) Aeration ratio (AR); (C) Permeability test results of LAC. (a) Pressure drop (PD) across the powder bed vs. applied normal pressures of LAC; (b) Permeability vs. applied normal pressures of LAC (All data were presented as mean ± SD, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.005, n = 3).

More energy was consumed to conquer the FF between particles, when the blade moved through the powders (Fig. 5Ad and e). Therefore, the TE values increased along with larger particle size of LAC. LAC1 possessed the lowest TE and the best flowability, which suggested superior aerosolization performance. In the last three test cycles, the TE values of LAC2 increased slightly then remained stable, while LAC3‒4 increased obviously then decreased to the level before. The tip speed of the blades was decreased in the last three test cycles, and higher TE was needed to move the blades for powder with higher Ra and inferior flowability. Since the tip speed in the last cycle was very low, particles had enough time to move behind the blades and the resistance to the front of the blades decreased. Thus, the TE values of LAC3‒4 decreased in the last test cycle. Besides, there was no significant change of the TE values of LAC1, suggesting its good flowability. In contrast, LAC1 presented the upward trend of TE at smaller blade speed (10 mm/s) and the change of the TE values of LAC1 was slight, suggesting its good flowability.

The BFE values increased as the LAC of larger particle sizes were used in the test (Fig. 5Ab), which indicated the deterioration of flowability and verified the results from the TE values. In addition, the SE values increased from LAC1 to LAC3, while there was no obvious difference between LAC3 and LAC4 (Fig. 5Ac). Higher SE values suggested stronger total FI in each gram of powder. LAC1 had the lowest SE values, which was beneficial to the detachment of carrier and drug during pulmonary delivery. Besides, each particle of LAC3 possessed smaller Ra and mass than LAC4, which resulted in smaller FI between two particles. However, it was counterbalanced and surpassed by the larger quantity of LAC3 particles under the same quality conditions, due to its smaller particle size and density. Thus, the SE values of LAC3 and LAC4 were similar.

The TE, AE and AR values acquired from aeration test are presented in Fig. 5B. The aeration test was employed to evaluate the decrement of flow energy when air flow was introduced. It was applied to depict the powder behavior of DPIs during blending process, fluidization and transportation processes, which was of significance for pulmonary delivery efficiency,. The TE of LAC1 and LAC2 became stable when air velocity reached four and 8 mm/s, respectively (Fig. 5Ba). The stable state of TE indicated fully fluidization of powder and minimum air velocity that reached fluidized state (minimum fluidize velocity, MFV). Lower MFV of LAC1 suggested that it was easier to be fluidized and delivered into deep lung. In addition, the TE values of LAC3 and LAC4 barely reached stable at 10 and 25 mm/s, respectively, demonstrating they were harder to be fluidized compared with LAC1‒2 (Fig. 5a and b). It may be due to the larger FG and FI of LAC3‒4 led to prematurely deposition during pulmonary delivery processes. Furthermore, the higher AE and AR values meant the powder were more cohesive and more sensitive to air flow, respectively,. LAC1 and LAC2 both possessed low AE values, showing their small cohesive force during aeration (Fig. 5Bc). Meanwhile, the AE values of LAC1 were slightly higher than that of LAC2, which might result from higher Coulomb force in LAC1. LAC1 possessed smaller particle size than LAC2, indicating that the voids between particles in LAC1 were also smaller. When aerated, particle friction generated static electricity and the Coulomb force that reduced the distance between particles. A little extra energy was needed to be surmounted when LAC1 aerated. However, the effect of Coulomb force decreased with the increasing of particle size. Therefore, the AE values of LAC1 were slightly higher than that of LAC2. LAC4 had the highest AE values, suggesting the largest cohesive force of LAC4. Moreover, the AR values of LAC2 are much higher than that of other LAC samples (Fig. 5Bd). The results showed that the balance of particle size, Coulomb force and Ra ensured the superior sensitivity of LAC2 to air flow.

The PD and permeability values obtained by permeability test are shown in Fig. 5C. Permeability test was used to measure the ease of air flow passed through powder under various pressures. The lower PD values suggested higher permeability, which were beneficial for better dispersion, fluidization and transportation of DPIs. The PD values of all LAC samples were small and almost remained stable when applied normal stress increased, showing good permeability of LAC (Fig. 5Ca). The PD values decreased and the permeability increased when the particle size increased (Fig. 5Cb). This could be explained as that the voids between particles increased with the increment of particle size, which was easier for the air flow to pass through and showed higher permeability.

Carrier served as a fundamental component in carrier-based DPIs due to its high proportion. Hence, the physicochemical properties of carrier had an essential influence on aerosolization performance of DPIs. Carriers with different particle size possessed various inertia and drug payload, and were subjected to different degrees of FD, FG and FI which greatly affected the PDPs and pulmonary drug delivery efficiency. Therefore, MPAP was employed to explore the effect of CPS on PDPs with a model DPIs. To be specific, the fluidization and dispersion of DPIs in inhaler device, the transportation, detachment and deposition in artificial throat and pre-separator were investigated in detail. In addition, the mechanism of carrier particle size on each PDP was explored.

Configuration A: With inhaler device

Primarily, the inhaler device was equipped on the laser particle size analyzer to obtain configuration A (Fig. 3A). The PDP of DPIs in inhaler device was expounded with the real-time release profile of drug, drug aggregation and carrier. In addition, the RAUC served as an indicator to show the detachment and deposition of DPIs. Thus, the impact of CPS on the fluidization, dispersion and premature deposition of DPIs in the inhaler device was explored.

The release profiles of DPIs with different CPS are presented in Fig. 6A. The R values increased in the first place and decreased subsequently, which was similar to the breath of human. The Rmax (Fig. 6A) and RAUC (Fig. 6B) of DPIs increased along with the decrease of CPS. DPI1 exhibited the highest Rmax, which was 1.43-, 1.60-, and 2.41-fold of DPI2, DPI3 and DPI4, respectively. Meanwhile, the RAUC of DPI1 was much higher than that of DPI4 (2.98-fold). Good linear relationships between Rmax and D50 of corresponding LAC (R = 0.9967) as well as RAUC and D50 of corresponding LAC (R = 0.9802) were established, respectively.

Figure 6

Configuration A (A) Release profiles of DPIs. Inset was the correlation between D50 of LAC and Rmax; (B) Total release amount; (C) Force analysis of DPIs in the capsule within inhaler device; (D) DPIs with larger CPS remained in the capsule or deposited prematurely; (E) The release of DPIs with larger CPS; (F) The release of DPIs with smaller CPS (all data were presented as mean ± SD, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.005, n = 3).

The DPIs particles were subjected to many forces when being released from the capsule, which primarily consisted of the drag force of air flow [FD, Eq.(2)],, FG [Eq.(3)], FI, and FF between particle–particle and particle-capsule wall (Fig. 6C).where η represents the viscosity of the air, X denotes the dynamic shape factor, d represents the diameter of particle, CC is the Cunningham correction factor for slip flow, ρ represents the bulk density, m represents the mass of particle and V is the volume of particle.

Of note, FD and FG dominated the release process of particles from the inhaler device. According to Eqs. (2), (3), FG was more influenced by particle diameter (d) than FD, since FG was proportional to the third power of d. When CPS increased, FG of DPIs particles increased drastically. Meanwhile, higher Ra also led to larger FF. It was relatively hard for larger DPIs particles to be entrained by air flow. Instead, they tended to remain in the capsule, deposit early (Fig. 6D) or release slowly from the capsule to reach the detector (Fig. 6E), resulting in low Rmax and RAUC values. The results revealed that DPIs with larger CPS were prone to deposit on oropharynx and could not travel further for deeper drug delivery.

In comparison, DPIs with smaller CPS were subjected to lower FG and Ra, which allowed them easier to be fluidized, dispersed and released from the capsule to successfully reach the detector (Fig. 6F). The increased Rmax and RAUC of the DPIs with smaller CPS enabled the particles to be delivered into lower respiratory tract. Furthermore, the tendencies of Rmax and RAUC of DPIs confirmed the results of TE (Fig. 5Aa) and MFV (Fig. 5Ba and b), suggesting that LAC with smaller particle size had less resistance to air flow and was easier to fluidize. Moreover, the release profile of carrier was similar to that of DPIs, indicating weak detachment between drug/drug aggregation and carrier within inhaler device (Supporting Information Section 5). Regarding to drug and drug aggregation, Rmax and RAUC also increased with the smaller CPS and the detailed results were presented in Supporting Information Section 5.

In short, the fluidization and dispersion processes of DPIs with different CPS were monitored by configuration A. The release profiles showed that DPIs with smaller CPS were easier to be fluidized and released from the capsule when inhaled. It showed that DPIs with smaller CPS were prone to be transported into deeper airway instead of premature deposition. Meanwhile, the detachment between drug/drug aggregation and carrier increased with smaller CPS due to lower Ra and fewer active sites of smaller size carrier that reduced drug adhesion, and more severe impaction that promoted detachment. Thus, smaller CPS was considered more suitable for further transportation, but its possible adverse effect also needed to be considered owing to higher drug detachment.

Configuration B: With inhaler device & artificial throat

Configuration B was achieved by using the inhaler device and the artificial throat connected to the laser particle size analyzer by a customized connector (Fig. 3B), which was employed to explore the effect of throat on the transportation and detachment processes of DPIs.

Comparing to configuration A, all Rmax and RAUC of release profiles obtained by configuration B obviously declined, mainly due to the direction change of air flow caused by artificial throat. The release profiles obtained by configuration B were shown in Fig. 8. Tt, Rmax (Fig. 7A and D) and RAUC (Fig. 7E) of DPIs and carrier increased with smaller CPS. Specifically, Rmax of DPI1 was 1.19-, 2.10- and 2.78-fold of that of DPI2, DPI3 and DPI4, respectively. A linear correlation (R2 = 0.9450) between Rmax of DPIs and D50 of the corresponding LAC was observed. Notably, RAUC of DPI1 was 2.45-fold of that of DPI4.

Figure 8

Configuration C (A) Release profiles of DPIs; (B) Release profiles of drug; (C) Release profiles of drug aggregation; (D) Release profiles of carrier; (E) Total release amount; (F) Carrier tended to deposit on pre-separator while drug could be further entrained by airflow; (G) Detachment of carrier‒drug/drug aggregation and dispersion of drug aggregation due to different FC (All data were presented as mean ± SD, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.005, n = 3).

Figure 7

Configuration B (A) Release profiles of DPIs. Inset was the correlation between D50 of LAC and Rmax; (B) Release profiles of Drug; (C) Release profiles of drug aggregation; (D) Release profiles of carrier; (E) Total release amount; (F) DPIs deposited before the corner of artificial throat; (G) The stopping distance of DPIs with larger CPS was longer than the distance between particle and the wall of artificial throat; (H) Drug aggregation was formed during transportation in artificial throat due to stronger impaction and Coulomb force (all data were presented as mean ± SD, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.005, n = 3).

When the CPS increased, the FG of DPIs increased consequently. Large FG and inadequate FD might give rise to deposition of DPIs particles on artificial throat rather than further transportation (Fig. 7F). Importantly, once DPIs particles reached the bend of artificial throat, they still had a velocity (V0) towards the original orientation that kept particles moving forward. The required distance for reducing V0 to zero was referred as stopping distance [S, Eq.(4)].where η is the viscosity of the air, X represents the dynamic shape factor, d denotes the diameter of particle, ρ is the bulk density and CC represents the Cunningham correction factor for slip flow.

Inertial impaction and particle capture might take place when S was longer than the distance between the particles and the wall of artificial throat. According to Eq. (4), S was proportional to the second power of d, indicating that particles with larger size needed a longer stop distance and were more likely to collide with the wall of artificial throat and be captured, leading to less drug to reach the lung (Fig. 7G). Thus, Rmax and RAUC of DPIs and carrier decreased with larger CPS.

Regarding to the release profiles of drug, DPI2 possessed the highest Rmax (Fig. 7B). RAUC of DPI1 was 1.29- and 1.79-fold of that of DPI3 and DPI4, respectively, while DPI2 was slightly higher than DPI1 (Fig. 7E). Besides, Rmax and RAUC of drug aggregation decreased with increased CPS (Fig. 7C and E).

As previously mentioned, RAUC of DPIs increased with smaller CPS and hence the detachment of drug and drug aggregation increased due to the lower Ra of carrier and fewer active sites as well as stronger impaction between particles. Meanwhile, when DPIs particles entrained by air flow and entered artificial throat, they were in a fully fluidized state. The EDXS images and AE, AR values obtained in aeration test could be applied to analyze the above results. For DPI1, larger proportion of drug particles did not adhere to the active sites on carrier surface (Fig. 4E). Moreover, its smaller CPS resulted in greater chance of impaction, which generated more static electricity and showed higher AE values and lower AR values. As a result, drug particles in DPI1 were easier to form drug aggregation due to stronger impaction and Coulomb force (Fig. 7H). In contrast, carrier of DPI2 possessed larger Ra and more active sites. Smaller drug aggregations were formed during blending process compared to DPI1, which were easier to be dispersed into drug particles. Meanwhile, less static electricity was generated for dispersed drug particles to reform aggregation in larger CPS. Hence, RAUC of drug in DPI2 was higher than that of DPI1 while RAUC of drug aggregation in DPI2 was lower. However, the detachment of drug from carrier within throat was not beneficial to high pulmonary drug delivery efficiency.

It was well-known that when the detached drug particles released from throat in the human body, they would enter the long and moist trachea. Due to the stronger electrostatic force and poorer flowability of fine particles, the drug particles detached in inhaler device or throat were more likely to adhere to the wall of trachea and had smaller chance to travel into the lower parts of airways.

Besides, the internal geometry was more complex than artificial throat in real human body and moist mucus layers also existed, which might lead to more particle deposition without bouncing back. Thus, the Alberta throat with more detailed internal geometry and 1% Tween® 80 could be applied in the future study for acquiring more realistic correlation between in vitro simulation and in vivo.

In summary, configuration B of MPAP was demonstrated useful in the investigation of DPIs transportation and detachment. Since the deposition of DPIs particles before the bend of artificial throat and inertial impaction with the wall of artificial throat hindered the further transportation of DPIs, RAUC of DPIs were obviously lower than those in Configuration A. Besides, the release profiles and RAUC showed that the detachment of drug and drug aggregation from carriers became more distinct while CPS was smaller, since the lower Ra, fewer active sites of carrier and stronger impaction between particles–particles. However, the prematurely detached drug particles from carrier within the inhaler device or artificial throat endowed a great chance to be captured before reaching deep lung, which was not desirable for pulmonary drug delivery.

Configuration C: With inhaler device & artificial throat & pre-separator

Configuration C was obtained by using the inhaler device, the artificial throat and the pre-separator equipped to the laser particle size analyzer (Fig. 3C). Pre-separator was introduced to investigate the detachment process of DPIs in the bronchi bifurcation of human.

Compared with configuration B, the Rmax and RAUC of drug (Fig. 8B and E) significantly increased, while those of drug aggregation (Fig. 8C and E) and carrier (Fig. 8D and E) decreased in configuration C. DPIs particles were under the influence of centrifuge force (FC) besides FD and FG, when entered the pre-separator. According to Eq. (5), FC was proportional to the third power of d, which indicated a significant impact of d on FC.where m is the mass of particle, r represents the radius of centrifugal motion, d denotes the diameter of particle.

Since there were great differences between d of drug or drug aggregation and carrier, the FC of each subject varied. For carriers, they possessed larger particle size and bigger FC, so their movements tended to be close to the wall of pre-separator, resulting in bigger potential to deposit. In contrast, drug and drug aggregation with smaller particle size were inclined to move near the center of pre-separator. Different FC of these subjects generated the separation effect, which overcame the particle adhesion and promoted the drug detachment between drug aggregations or drug–carrier complex (Fig. 8G). Therefore, RAUC of drug markedly increased while RAUC of drug aggregation and carrier decreased.

The release profiles and RAUC obtained by configuration C were presented in Fig. 8. The Rmax and RAUC of DPIs (Fig. 8A) increased for smaller CPS, which mainly due to the increased detachment of drug particles. Although increased CPS would theoretically benefit the detachment due to the greater difference of FC, more active sites and higher Ra of larger CPS greatly restrained the drug detachment process. Besides, the larger specific surface area (SSA) of carrier with smaller particle size might result in more chance of adhesion and less detachment between drug and carrier. The Rmax and RAUC of drug (Fig. 8B and E) increased with smaller CPS, which proved that the quantity of active sites and Ra imposed greater influence than FC and SSA on the detachment process. Although in configuration B, DPI1 tended to form drug aggregations due to generated static electricity, the FC acted on drug aggregation might overcome this cohesive force and re-disperse the drug particles within the pre-separator (Fig. 8G), which also led to the highest Rmax and RAUC of drug in DPI1. The released drug particles within the pre-separator had greater chance to be efficiently transported into the lower parts of airways and deposited on the deep lung. The results showed that DPI1 had better drug detachment property and implied that LAC1 was optimal for efficient pulmonary drug delivery due to its suitable particle size and surface roughness.

DPIs with larger CPS would suffer from greater FG and consequently, lead to greater acceleration of downward movement (Fig. 8F), increased deposition on the bottom of the pre-separator and reduced time for drug detachment and eventually, lower Rmax and RAUC of carrier (Fig. 8D and E). On the contrary, the DPIs of smaller CPS (e.g., DPI1) had increased Rmax and RAUC and longer Tt of carrier, which proved to be able to facilitate further delivery of drug particles into deep lung.

In brief, the transportation and detachment processes within bronchi bifurcation of DPIs were mimicked by the configuration C. The detachment between drug and carrier in the pre-separator was more efficient than that in the artificial throat and inhaler device, due to the FC generated by vortex air flow within the pre-separator. During this process, the detached drug particles had greater potential to be delivered into deep lung, while carriers tended to deposit due to larger FG and FC. Besides, the CPS played important role in the detachment of DPIs. The Ra and quantity of active site in different carriers dominated the detachment process. LAC1 with the smallest particle size among all carriers possessed the lowest Ra and the fewest active sites. It was beneficial for detachment of drug and carrier, and thus became the optimal CPS in the present study.

NGI, which was the globally recognized method for the evaluation of in vitro aerosolization performance of DPIs,,, was employed in the present study to explore the influence of CPS on the PDPs of DPIs. Besides of the investigation on drug particles, the carrier deposition was also measured to further understand PDPs.

The result of drug recovery rate measured by NGI was presented in Supporting Information Section 6, which were larger than 85% and met the requirement of NGI test. The FPF values increased with the decrease of CPS. DPI1 showed 3.49-fold FPF value to DPI4 (Fig. 9A). Most drug particles deposited on the pre-separator and the deposition increased with the CPS (Fig. 9B). In regards to the carrier (Fig. 9C), more than 95% of particles of LAC2‒4 deposited on the pre-separator and failed to reach lung. In contrast, a higher proportion (11.68 ± 0.89%) LAC1 entered the lower stages and facilitated deeper pulmonary drug delivery. It was obvious that DPI1 with the smallest CPS showed optimal aerosolization performance.

Figure 9

In vitro aerosolization performance of DPI1‒DPI4 (A) The FPF values; (B) Drug deposition profile; (C) Carrier deposition profile (All data were presented as mean ± SD, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.005, n = 3).

Since the Ra and the quantity of active sites of carrier increased with the larger particle size, detachment of drug particles from the carrier was more difficult. Meanwhile, carriers with larger size were subjected to larger FG, which led to greater possibility to deposit on the pre-separator. Hence, DPIs with smaller CPS were considered as the better system in the present study (e.g., LAC1) for their superior efficiency for pulmonary drug delivery. A good linear relationship (R2 = 0.9557) was established between the FPF and RAUC of drug in configuration C. The results confirmed that the MPAP was a feasible approach to evaluate the mechanism of PDPs during DPIs development.

Conclusions

The main aim of this study was to apply MPAP to investigate the effect of CPS and the mechanisms in the PDPs of DPIs. As a key factor in PDPs, the CPS was considered to have great influence in the efficiency of pulmonary drug delivery greatly and was comprehensively investigated in the present study. The surface morphology and powder properties of carriers with different particle sizes were explored. Then, the MPAP was innovatively employed to mimic the PDPs of DPIs with different CPS in inhaler device, throat and tracheal bronchus, respectively. The results of the experiments revealed that the Ra, quantity of active site and FG varied according to the different CPS, which led to different performance of PDPs. The RAUC of DPI1 was much higher than that of DPI4 (2.98-fold) in configuration A. Besides, the RAUC of drug in DPI1 was 3.68-fold of DPI4 in configuration C. According to the results of MPAP, DPIs with smaller CPS (e.g., LAC1) tended to undergo easier fluidization and dispersion in the inhaler device. Although drug particles of DPIs with the smallest CPS tended to aggregate because of stronger static electricity, their lower Ra and smoother surface were beneficial for the detachment process of drug from the carrier in the pre-separator, which eventually led to better performance of pulmonary drug delivery. For the range of particle size in the present study (41.66–194.17 μm), the optimal applicable range of CPS of DPIs was 41.66–91.70 μm. However, the applicable range of CPS needed to be subdivided and expanded to obtain a more precise result, which could be applied in the manufacture of DPIs. In conclusion, this study confirmed that the physicochemical properties of carrier with various particle sizes were the key parameters to understand the mechanism of PDPs. Incorporating these factors into a real-time monitoring system such as MPAP would be highly feasible and promising to facilitate the development of DPIs.